Accepted Manuscript

Progesterone and Preterm Birth Prevention: Translating Clinical Trials Data into Clinical Practice

Vincenzo Berghella, The Society for Maternal-Fetal Medicine: Publications Committee

PII: S0002-9378(12)00291-8
DOI: 10.1016/j.ajog.2012.03.010
Reference: YMOB 8681


Received date: 12 March 2012
Accepted date: 13 March 2012


This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Progesterone and Preterm Birth Prevention: Translating Clinical Trials Data into Clinical Practice.

SMFM Clinical Guideline

From the Society for Maternal-Fetal Medicine Publications Committee with the assistance of Vincenzo Berghella, Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA

Address all correspondence to:
The Society for Maternal-Fetal Medicine: Publications Committee.
409 12th Street, SW
Washington, DC 20024
Phone: 202-863-2476
Fax: 202-554-1132
E-Mail: pubs@smfm.org

Reprints will not be available
Abstract

Objective: To provide evidence-based guidelines for utilization progestogens for the prevention of preterm birth (PTB).

Methods: Relevant documents, in particular randomized trials, were identified using PubMed (US National Library of Medicine, 1983 to February, 2012) publications, written in English, which evaluate the effectiveness of progestogens for prevention of preterm birth. Progestogens evaluated were, in particular, vaginal progesterone and 17α hydroxyl-progesterone caproate (17P). Additionally, the Cochrane Library, organizational guidelines, and studies identified through review of the above were utilized to identify relevant articles. Data was evaluated according to population studied, with separate analyses for singleton vs multiple gestations, prior PTB, or short transvaginal ultrasound (TVU) cervical length (CL), and combinations of these factors. Consistent with U.S Preventive Task Force suggestions, references were evaluated for quality based on the highest level of evidence, and recommendations were graded.

Results and Recommendations: Summary of randomized studies indicates that in women with singleton gestations, no prior PTB, and short CL ≤20 mm at ≤24 weeks, vaginal progesterone, either 90mg gel or 200mg suppository, is associated with reduction in PTB and perinatal morbidity and mortality, and can be offered in these cases. The issue of universal cervical length screening of singleton gestations without prior PTB for the prevention of preterm birth remains object of debate. Cervical length screening in singleton gestations without prior preterm birth cannot yet be universally mandated. Nonetheless, implementation of such a screening strategy can be viewed as reasonable, and can be considered by individual practitioners, following strict guidelines. In singleton gestations with prior PTB 20-36 6/7 weeks, 17P 250mg IM weekly, preferably starting at 16-20 weeks until 36 weeks, is recommended. In these women with prior
preterm birth, if the TVU CL shortens to <25mm before 24 weeks, cervical cerclage may be offered. Progestogens have not been associated with prevention of PTB in women who have in the current pregnancy multiple gestations, preterm labor, or preterm premature rupture of membranes. There is insufficient evidence to recommend the use of progestogens in women with any of these risk factors, with or without a short CL.

**Keywords**: progestogens, vaginal progesterone, 17-alpha hydroxyl-progesterone caproate, prior preterm birth, cervical length, preterm birth
**Introduction**

Progesterone was isolated and characterized in 1934, and its role in myometrial quiescence was first reported in 1954. (1,2) From 2003 to 2011, several randomized trials evaluating the effect of either 17 hydroxy-progesterone caproate (17P) given intramuscularly (IM), natural progesterone given vaginally or orally for prevention of preterm birth (PTB), have been published. The term ‘progestogens’ includes both vaginal progesterone and 17P.

Given this large amount of new important information, the scope of this manuscript is to review the level 1 evidence (RCTs, and meta-analyses of RCTs) evaluating the role of progestogens in the prevention of PTB, and to provide clinicians with current recommendations for their use in possible clinical scenarios. Other publications have not addressed the totality of this new information. (3-5)

As 17P and vaginal progesterone may vary in their effect (6,7), they will be addressed separately. The effects of interventions for reduction of PTB often vary by the population studied, and in particular by major risk factor categories for PTB. Major differences exist when analyzing effects of other interventions by number of fetuses (i.e. singleton vs multiple gestations), prior PTB (vs not), and short cervical length (CL) on transvaginal ultrasound (TVU) (vs not). (8). Therefore data will be analyzed according to these major categories of risk.

**What are the mechanism of action and safety data of progestogens?**

The mechanisms of action and safety of progestogens are not the purpose of this review, and are discussed only briefly. While the exact mechanism of action of progestogens in preventing preterm birth is unknown, several possibilities have been proposed. (Table 1) (9-17) In general, the evidence seems to favor 2 mechanisms: an anti-inflammatory effect that counteracts the
inflammatory process leading to PTB, and a local increase in progesterone in gestational tissues that counteracts the functional decrease in progesterone leading to PTB. (Table 1) (9-17)

Regarding safety, several studies failed to detect any long term effect from the intrauterine exposure of the fetus to pharmacologic progestogens, even when given in the first trimester. (18) Follow-up, at a mean of 4 years, of 278 children randomized in the largest RCT evaluating 17P for prevention of recurrent PTB revealed no differences in physical examination, health status, or performance (motor, problem solving, personal-social) compared to placebo. (19)

**What is the evidence and recommendation for use of progestogens for prevention of PTB in:**

- **Singleton gestations with no prior preterm birth, with unknown CL?**
  - **17P:**
    
    In 168 women in active military duty with only a 3% rate of prior PTB and unknown CL, 17P 1,000mg IM weekly starting at 16-20 weeks was not associated with any effect on the incidence of PTB or perinatal outcomes compared to placebo. (20)

  - **Vaginal progesterone:**
    
    No RCT has evaluated the effect of vaginal progesterone in this population.

    *In summary*, there is insufficient evidence to determine the impact on PTB of progestogens in singleton gestations with no prior history of preterm birth, and with unknown or normal CL.
• **Singleton gestations with no prior PTB, but short CL?**

17P:

It is particularly important to assess the effectiveness of progesterone in women without prior PTB, as most PTBs occur in this population. In 657 nulliparous women with singleton gestations with TVU CL ≤ 30mm at 16-22 3/7 weeks, 17P 250mg intramuscularly weekly through 36 weeks was associated with similar incidences of preterm birth < 35 weeks (13.5% vs 16.1%; p=0.35) and < 37 weeks (25.1 vs 24.2%; p=0.80), compared to placebo. (21) This RCT was stopped due to a planned interim analysis that revealed further enrollment was statistically very unlikely to demonstrate a significant difference between the groups.

In 79 women with singleton pregnancies (66% of whom had no prior PTB) with TVU CL < 25mm between 16-24 weeks, 17P was associated with similar rates of preterm birth and neonatal morbidity and mortality compared to cerclage. (22) Cerclage was significantly more effective than 17P at reducing the incidences of PTB <35 weeks and < 37 weeks in the subgroup with TVU CL ≤ 15mm. (22) This RCT was stopped before planned recruitment was completed as the authors stated that ‘it had become impractical, unethical, and unreasonable to withhold progesterone from one study group.’

**Vaginal progesterone:**

In 250 women from U.K., Chile, Brazil, and Greece, with mostly (90%) singleton gestations and TVU CL ≤15mm at 20-25 weeks, of whom about 85% had no prior PTB, vaginal progesterone 200mg nightly started at 24 weeks until 34 weeks was associated with a 44% significant decrease in SPTB <34weeks (19% vs 34%; RR 0.56, 95% CI 0.36-0.86), but no significant effect on neonatal morbidities (composite neonatal adverse outcome: RR 0.57, 95% CI 0.23-1.31). (23) A subgroup analysis of only women without prior PTB confirmed significant
benefit of progesterone in preventing PTB <34 weeks (RR 0.54, 95% CI 0.34-0.88). (23) The prevalence of TVU CL ≤15mm in the population screened for the study was 1.7%. Based on the frequency of short TVU CL and effectiveness for prevention of spontaneous PTB <34 weeks from the work of Fonseca et al, the number of women needed to be screened with CL in order to prevent one spontaneous PTB <34 weeks is approximately 387, if all women with a CL ≤15mm receive vaginal progesterone. Once a TVU CL ≤15mm is identified, the number needed to treat to prevent one PTB <34 weeks is about 7.

In 458 women with singleton gestations and TVU CL 10-20mm at 19-23 6/7 weeks, of whom about 84% had no prior PTB, vaginal progesterone 90mg daily started at 20-23 6/7 weeks until 36 6/7 weeks was associated with a 45% significant reduction in PTB < 33 weeks (9 vs 16%; RR 0.55, 95% CI 0.33-0.92), and 43% significant reduction in composite neonatal morbidity and mortality (8 vs 14%; RR 0.57, 95% CI 0.33-0.99). (24) The incidences of PTB < 28 and < 35 weeks, and RDS, were also significantly decreased. Analysis of only women without prior PTB confirmed significant benefit of progesterone in preventing PTB < 33 weeks (8 vs 15%; RR 0.50, 95% CI 0.27-0.90). (24) The prevalence of CL 10-20mm was 2.3% in the population screened. The study enrolled patients in 44 centers in 10 countries (largest enrollment from U.S., 46% of total), and the ethnic distribution of those included was about a third Caucasian, a third African-American, and a third Asian. Protocol violations may have influenced the outcomes, and the study was both industry- and NIH-sponsored. After evaluating data from this trial only, the FDA concluded that the study did not meet the statistical significance generally expected to support the approval of the product in the US market from a single trial. The FDA raised the issue of robustness in efficacy in the US subgroup as compared to overall efficacy in the trial, and stated that additional clinical work would be required to support the
approval. (25) Based on the frequency of short CL and effectiveness for prevention of PTB <33 weeks from this study (24), the number of women needed to be screened with CL in order to prevent one PTB < 33 weeks is approximately 604, if all women with a CL 10-20mm receive vaginal progesterone. Once a TVU CL 10-20mm is identified, the number needed to treat to prevent one PTB <33 weeks is about 14. The study did not address the management of women with a CL <10 mm.

In a meta-analysis, including 554 singleton gestations, no prior PTB, and TVU CL ≤ 25mm mostly before 25 weeks, vaginal progesterone was associated with a significant reduction in PTB < 33 weeks (RR 0.60, 95% CI 0.39-0.92) and a non-significant reduction in composite neonatal morbidity and mortality (RR 0.70, 95% CI 0.42-1.16). (26)

Two cost-effectiveness analyses evaluating universal cervical length screening in singleton gestations, to identify those with short CL eligible for vaginal progesterone, have been published so far. (27,28) Both reported that such a strategy would be cost-effective. In one study, compared to other managements, including no screening, ‘universal’ sonographic screening of CL in singletons was predicted to results in a reduction of 95,920 preterm births < 37 weeks annually in the US, and was actually cost-saving (almost $13 billion saved). (27) Even varying the assumptions (e.g. the cost of vaginal progesterone or of TVU screening), universal screening was the preferred strategy 99% of the time. (27)

The other cost-effectiveness analysis targeted women with singleton gestation without prior PTB. A strategy of universal screening with a single TVU CL at 18-24 weeks and treatment with vaginal progesterone if the cervical length was ≤ 1.5cm, resulted in over $12 million saved, 424 quality adjusted life-years (QALY) gained, and 22 neonatal deaths or long-term neurologic deficits prevented for every 100,000 women screened compared with no screening. Even varying
the assumptions over a wide range of possible values (e.g. the cost of vaginal progesterone or of TVU screening), universal screening was cost-effective over 99% of the time. (28) This cost-effectiveness analysis initially addressed only women with a TVU CL ≤ 1.5 mm. In an addendum, the authors mention that a re-analysis adding progesterone treatment for women with TVU CL between 1.6 to 2.5 mm did not change their conclusions, with the details of the re-analysis not provided.

In summary, in women with singleton gestations, no prior SPTB, and short TVU CL, vaginal progesterone is associated with reduction in PTB and composite perinatal morbidity and mortality. Based on these results (23,24), if a TVU CL ≤20 mm is identified at ≤24 weeks, vaginal progesterone can be offered for prevention of PTB. The 2 studies used different progesterone preparations and dosages. Vaginal progesterone 200mg suppository was used in the trial for CL ≤15mm (23), and 90mg gel for the trial for CL 10-20mm (24). There is insufficient evidence that any of the vaginal preparations or doses is superior, as they have not been compared. CL, cost, availability, and other factors may influence preferred dosing. (27,28)

A decision of whether to institute a policy of universal screening for short cervix with TVU in women with singleton gestations without prior PTB requires several careful considerations:

- The available trials have addressed efficacy of progesterone for women identified with a short cervix. There are no data regarding effectiveness of universal screening for short cervix followed by vaginal progesterone for those with a short cervix, compared to no screening. The only evidence in favor of such an approach is based on cost-effectiveness analyses.
It is possible that a proportion of women with a short cervix may be identified without a specific universal transvaginal ultrasound screening. This may result in a lower than estimated added benefit of universal screening over current practice of visualization of the cervix on all transabdominal ultrasound performed in the second trimester. Data is currently insufficient to suggest benefit, or harm, of transabdominal screening of CL for prevention of preterm birth using progesterone or any other intervention as therapy if a short CL is identified.

Universal screening approach may not produce the same results in practice as those in a controlled trial. The latter may be due to differences in population, logistical differences in screening methods, stretching of the eligibility and management criteria (scope creep), and unintended consequences of universal screening. Performing multiple ‘follow-up’ scans, doing them outside of the studied gestational age (18-24 weeks), applying the treatment to women outside the studied CL range, or using other interventions for a short CL, such as bed rest or cerclage, may potentially result in adverse unintended consequences. The eligibility criteria were different between the 2 RCTs, and neither included all the women who had a CL below what is traditionally considered as short in the US (< 25 mm). The Fonseca et al. trial did not include women with a CL between 15 and 25 mm, and the Hassan et al. trial did not include women with a CL <10 mm or between 20 and 25 mm. Neither trial included women with CL > 20 mm, and therefore there is no evidence that vaginal progesterone is beneficial in these women. (23,24,26) It should be noted that only 1.7-2.3% of women were identified to have short CL in the two large trials published, (23,24) but that the
incidence of CL ≤20 mm at 22-24 weeks in the largest blinded US study was 5%.

(29) The use of different progesterone formulations (90mg gel and 200mg suppository) between the 2 trials should also be taken into account. There is no evidence that the two preparations are interchangeable in that the one which was efficacious in the 10-20 mm range would also be efficacious in those with a CL <10mm. In a meta-analysis, both of these two preparations had similar significant efficacy. (26)

- If an approach of universal screening is to be adopted, then TVU CL screening needs to be done with proper technique and with quality assurance in order to be effective.
- There may be lack of availability of this screening test in some geographic areas.

All of the above need to be taken into consideration when deciding on whether to change prenatal care for million of women by instituting universal screening with a single TVU assessment of CL at around 18-24 weeks in women with a singleton gestation without prior spontaneous PTB. On the other hand, TVU CL screening of singleton gestations does fulfill many criteria for an effective screening test (Table 2). (30-32) A number of experts have recommended TVU CL universal screening. (33-35) This is based mostly, in addition to what is listed on Table 2, on the following facts:

- There is level 1 evidence of prevention of PTB and neonatal benefits based on treating with vaginal progesterone low-risk singleton gestations identified with TVU screening to have a short CL.
This strategy is not only beneficial in terms of improvement in health in a condition (PTB) of outmost importance to society, but also cost-effective, and in fact cost-saving.

TVU CL is a safe, acceptable, reproducible and accurate screening test, with potentially widespread availability.

Therefore, both proponents and opponents of universal screening raise valid issues. Cervical length screening in singleton gestations without prior preterm birth cannot yet be mandated universally. Nonetheless, implementation of such a screening strategy should be viewed as reasonable, and can be considered by individual practitioners. Third-party payers should not deny reimbursements for this screening. Practitioners who decide to implement universal cervical length screening should follow strict guidelines:

TVU CL needs to be performed with proper technique in order to yield accurate results, with quality control and monitoring. To ensure quality, the Perinatal Quality Foundation is setting up a program on the proper training for clinical use of TVU CL measurement.

Randomized trials and cost-effectiveness studies were mostly based on performing a single TVU CL at 18-24 weeks on singleton gestations, and on using vaginal progesterone, either 90mg gel or 200mg suppository, as intervention when the TVU CL was ≤20mm before 24 weeks. Clinicians should refrain from screening different populations, at different gestational ages, and from stretching the definition of short CL to include measurements above 20 mm. There is also no evidence that other preparations (e.g. intramuscular 17P) or doses would be efficacious, even within the specified CL range.
• **Singleton gestations with prior preterm birth, and unknown or normal CL?**

**17P:**

In 43 women with mostly singleton gestation (>90%) and either prior PTB or > 1 prior spontaneous abortion, 17P 250mg IM weekly started as soon as prenatal care began was associated with significant reduction in PTB <37 weeks and perinatal mortality, compared to placebo. (36)

In 463 women with singleton gestation and prior SPTB at 20-36 6/7 weeks of a singleton gestation, compounded 17P 250mg IM weekly started at 16-20 6/7 weeks was associated with reduction in the incidences of PTB <35 (RR 0.66, 95% CI 0.54-0.81), PTB < 37 and <32 weeks, as well as of supplemental oxygen and IVH, compared to placebo. (6) Based mostly on this clinical trial, 17P has been recommended for all women with prior SPTB 20-36 6/7 weeks (3,5) The estimated number of prevented PTBs < 37 weeks in the US by this policy is about 9,870 annually. (37)

While the best evidence for efficacy is for 17P to be started before 21 weeks, beneficial effects have been reported when 17P is started by ≤27 weeks (38,39) 17P should not be stopped early (eg <32 weeks), as this is associated with increased incidence of PTB. (40)

**Vaginal progesterone:**

In 142 women with singleton gestations and mostly prior PTB (>90%), vaginal progesterone 100mg nightly from 24 to 34 weeks was associated with significant reduction in the incidences of PTB < 37 weeks (RR 0.48, 95% CI 0.25-0.96) and < 34 weeks, as well as reduction in contraction frequency, compared to placebo. (41)
In 659 women with singleton gestation and prior SPTB 20-35 0/7 weeks, vaginal progesterone 90mg every morning starting at 18-22 6/7 weeks and continued until 37 0/7 weeks was not associated with significantly different rates of PTB < 37, 36, 33, 29 weeks and neonatal morbidity and mortality. (7) Several women screened for this trial were excluded because of short CL. (7)

**Effect of progesterone on CL:**

In singleton gestations with prior PTB, 17P has not been associated with an effect on the development of short CL. (42) On the other hand, vaginal progesterone was associated with significant reduction in the incidence of short CL in women with singleton gestations and prior PTB. (16)

**Oral progesterone:**

In 148 women with singleton gestation and prior SPTB 20-36 6/7 weeks, oral progesterone 100mg twice a day was associated with significantly reduced rates of PTB <37 weeks and NICU admission compared to placebo. (43) In 33 women with singleton gestation and prior PTB 20-36 6/7 weeks, oral progesterone 400mg daily was associated with trend (but no significant differences) for reduced rates of PTB <37 weeks (26 vs 57%; p=0.15) and ventilator use (0 vs 21%; p=0.07) compared to placebo (44)

*In summary*, in women singleton gestation with prior SPTB, in which CL is unknown, progestogen administration is beneficial in preventing PTB. Although we have limited data comparing the different preparations of progestogens, there is at present stronger evidence of effectiveness for 17P than for vaginal progesterone, based on the 2 largest trials. (6,7) Therefore, 17P 250mg IM weekly starting at 16-20 weeks until 36 weeks should be recommended to women.
with singleton gestations and prior SPTB 20-36 6/7 weeks. In cases in which 17P is unavailable, other progesterone preparations may be considered. (41)

- **Singleton gestations with prior PTB, and short CL?**
  
  **17P:**
  
  There are no RCTs evaluating the effectiveness of 17P compared to placebo in women with singleton gestations, prior PTB, and short CL. In this population, 17P has only been evaluated as an adjunct or an alternative to cervical cerclage.

  In singleton gestations with prior SPTB and a short TVU CL <25mm before 23 weeks, 17P was associated with statistically significant decrease in PTB <24 weeks and perinatal death in women not receiving cerclage in a secondary analysis of a cerclage trial (45). Beneficial effects of 17P were noted primarily for women with CL15-24.9 mm, while they were non-significant for women with CL <15 mm. Overall, women with a cervical length < 25mm had a 34% risk of PTB < 32 weeks if they received neither 17P nor cerclage, 25% if they received cerclage, 21% if they received 17P, and 17% if they received both. (45) While these results were not statistically significant, they suggest that further research is needed to evaluate the relationship and possible cumulative beneficial effect of progesterone and cerclage.

  In a randomized trial which did not recruit the planned sample size, 17P and cerclage had similar effects in preventing PTB in women with a TVU CL <25 mm, but cerclage was more beneficial in women with CL <15 mm (22). While cerclage seems to be more efficacious (lower RRs) for CL on the lower end of the range (46,47), progesterone seems to be most efficacious for ‘moderately’ short CL. (23,24)

  **Vaginal progesterone:**
In a secondary analysis of an RCT (7) evaluating just the 46 singleton gestations with prior SPTB <35 weeks and short TVU CL<28 mm at 18-22 6/7 weeks, vaginal progesterone 90mg daily started at 18-23 6/7 weeks until 37 weeks was associated with significant decreases in the rates of both PTB <32 weeks and NICU admission, compared to placebo. (48)

In 71 singleton gestations with prior PTB, vaginal progesterone 100mg suppositories daily between 24-34 weeks was associated with significant reduction in incidences of PTB < 37 weeks (24% vs 50%; OR 3.11, 95% CI 1.13-8.53) and <34 weeks (5.4% vs 26.5%; OR 6.30, 95% CI 1.25-31.70), compared to placebo (49)

In a meta-analysis, including 169 singleton gestations with prior PTB and TVU CL ≤ 25mm mostly before 25 weeks, vaginal progesterone was associated with a significant reduction in PTB < 33 weeks (RR 0.54, 95% CI 0.30-0.98) and in composite neonatal morbidity and mortality (RR 0.41, 95% CI 0.17-0.98). (26)

Based on the pooled results of five clinical trials, in 504 singleton pregnancies with prior spontaneous PTB at less than 34 weeks and TVU CL < 25 mm before 24 weeks’ gestation, cerclage was associated with a significant 30% reduction in the risk of PTB < 35 weeks (28% versus 41%; RR, 0.70; 95% CI, 0.55—0.89) and a 36% reduction in composite perinatal mortality and morbidity (16% versus 25%; RR, 0.64; 95% CI, 0.45–0.91) (8). Therefore screening women with singleton gestations with prior spontaneous PTB with TVU CL starting usually at 16 weeks and every 2 weeks until 23 weeks is suggested, so that cerclage can be offered for those who develop a TVU CL < 25mm. As the vast majority of women included in this meta-analysis and its included randomized trials did not receive 17P, there is insufficient evidence to determine if the concurrent use of progesterone and cerclage offers an additive effect in reducing the risk of preterm birth in this group of women with prior preterm birth. (50)
Therefore, the optimal management of the patient with progressive cervical shortening despite progesterone therapy remains uncertain.

In summary, 17P should be recommended to women with prior SPTB starting at 16 weeks, as described above. If the cervix shortens <25mm by TVU before 24weeks in such a woman with singleton gestation and prior SPTB, there is insufficient evidence to assess efficacy of a different progesterone therapy, and therefore it is reasonable to continue 17P until 36 weeks, and to offer cervical cerclage.

- **Multiple gestations, and unknown or normal CL?**

  **17P:**

  In 77 women with twin gestation, 17P 250mg IM weekly from 28 to 33 weeks was not associated with any effect on PTB rates or perinatal morbidity and mortality, compared to placebo. (51)

  In 655 women with DC twin gestation, of whom <10% had prior PTB, 17P 250mg IM weekly starting at 16-20 weeks and ending at 35 weeks was not associated with any effect on PTB rates or perinatal morbidity and mortality in a NICHD-sponsored RCT, compared to placebo. (52)

  In 30 women with twin gestation, of whom 27% had a prior PTB, 17P 250mg IM weekly starting at 20-30 weeks and ending at 34 weeks was associated with similar incidences of PTB < 35 weeks and < 30 weeks, as well as similar rates of neonatal morbidity and mortality, compared to placebo. CL was not reported. (10)
In 240 women with DC twin gestation, 17P 250mg IM weekly starting at 16-24 weeks until 34 weeks was associated with similar incidences of PTB and neonatal morbidity, compared to placebo (53).

Two RCTs have evaluated the effect of 17P in triplet gestations. In a total of about 190 triplet gestations, 17P 250mg IM weekly started at around 16-20/22 weeks gestations until 34/35 weeks was not associated with effects on incidence of PTB or perinatal morbidity and mortality compared to placebo. (54,55)

Vaginal progesterone:

In 500 women with twin gestation, vaginal progesterone 90mg daily starting at 24 weeks and continued for at least 10 weeks was not associated with significant effects in incidences of PTB or perinatal morbidity and mortality, compared to placebo. (56)

In 677 women with diamniotic twin gestation, vaginal progesterone 200mg pessaries starting at 20-24 weeks until 34 weeks were not associated with significant effects on incidences of PTB or perinatal complications, compared to placebo (57).

In 67 twin gestations, vaginal progesterone 100mg suppositories daily between 24-34 weeks was associated with significant reduction in incidences of PTB < 37 weeks (51% vs 79%; OR 3.48, 95% CI 1.16-10.46) but not <34 weeks (10% vs 25%; OR 2.90, 95% CI 0.76-11.20), compared to placebo. (49)

No RCT has yet been reported on the effect of vaginal progesterone on triplet gestations.

In summary, the evidence does not support the use of any type of progestogen for prevention of PTB in multiple gestations with unknown CL. In women with prior spontaneous PTB, and a current multiple gestation, some experts have suggested the use of 17P starting at 16
weeks based on the historic risk factor (58), but there is insufficient evidence to make this a recommendation.

- **Multiple gestations, and short CL?**

  **17P:**

  In a secondary analysis of a trial involving women with dichorionic twin gestation, 52 women, of whom 18.5% had prior PTB, were identified to have a TVU CL of ≤ 35mm (25th percentile) between 16-20 weeks. 17P 250mg IM weekly starting at 16-20 weeks and ending at 35 weeks was associated with similar incidences of PTB < 35 weeks (64% vs 46%, p=0.18), compared to placebo. (59)

  **Vaginal progesterone:**

  In a secondary analysis of a trial involving women with diamniotic twin gestation, 47 women, of whom 9% had prior PTB, were identified to have TVU CL ≤ 30mm between 20-24 weeks. Vaginal progesterone 200mg pessaries starting at 20-24 weeks until 34 weeks was not associated with an effect on PTB < 34 weeks (29% vs 40%; RR 0.63, 95% CI 0.18-2.23), compared to placebo. (60)

  In a meta-analysis, including 52 twin gestations found to have a TVU CL < 25mm ≤ 24 weeks, vaginal progesterone was associated with similar incidence of PTB < 33 weeks (30% vs 45%; RR 0.70, 95% CI 0.34-1.44) and <35 weeks (52% vs 62%; RR 0.91, 95% CI 0.57-1.46), but a significant reduction in composite neonatal morbidity and mortality (24% vs 40%, RR 0.56, 95% CI 0.30-0.97), compared to placebo. (26)

  *In summary,* there is insufficient evidence to assess the effect of progestogens in women with both multiple gestation and short CL.
• **Preterm labor?**

**Primary tocolysis**

In 57 women admitted between 13-36 weeks with contractions, progesterone 400mg orally once was associated with a significant decrease in the frequency of contractions, but no PTB or neonatal outcomes were reported, compared to placebo. (61)

**Adjunctive tocolysis**

In 44 women with mostly singleton gestations (>90%) and threatened PTL at less than 35 weeks treated with ritodrine, natural progesterone 400mg orally q6hrs x 24hrs (then 400mg q8hrs for next 24hrs, and then 300mg q8hrs onwards) was associated with similar rates of PTB, but with lower total dose of ritodrine administered and shorter maternal hospital stay compared to placebo. (62)

**Maintenance tocolysis**

**17P:**

In 60 women with singleton gestation still pregnant after successful tocolysis for PTL, 17P 341mg twice weekly started at 25-33 6/7 weeks until 36 weeks was associated with significant reduction in the incidence of PTB <37 weeks (but not 35 weeks) and of risk of cervical shortening compared to no such treatment. (63)

In 188 women with singleton gestations still pregnant after successful tocolysis for PTL, 17P 500mg IM twice weekly started at 24-31 6/7 weeks until 36 weeks was associated with similar incidences of PTB <37, <34, and <32 weeks, and of perinatal morbidity and mortality compared to no such treatment (64)

**Vaginal progesterone:**
In 70 women with singleton gestation still pregnant after successful tocolysis for PTL, vaginal progesterone 400mg daily until delivery was associated with longer latency until delivery, later gestational age at delivery (PTB was not reported), and RDS compared to no such treatment. (65)

*In summary*, there is currently insufficient evidence to recommend progesterone primarily for, or as an adjunct to, tocolysis.

- **PPROM?**
  - **17P:**
    
    In 69 women with singleton gestations and PPROM at 24 to 30 weeks, 17P 250mg IM is associated with no effect on interval to delivery, gestational age at delivery, or neonatal mortality and morbidity in a small RCT. (11)

    **Vaginal progesterone:**

    No RCT has evaluated the effect of vaginal progesterone in this population.

    *In summary*, there is insufficient evidence to assess effect of progesterone in women with PPROM. In a woman who has been receiving 17P for prior spontaneous PTB, in the absence of evidence to the contrary, it is reasonable to continue 17P once membranes have ruptured.

**Conclusions**

Assessment of efficacy of progestogens for prevention of PTB should be done separately for each type of progestogens, with vaginal and intramuscular routes of administration the most studied types. Efficacy probably varies also depending on each different risk factor. In addition, dose, gestational age at initiation and termination, compliance, and other issues are factors that
influence efficacy of progesterone for prevention of PTB. Therefore, singleton vs multiple
gestation, prior history (e.g. prior PTB), short TVU CL (and degree of) or not, asymptomatic vs
PTL and PPROM, etc, are all factors which should be considered, as progestogens have different
effects in populations with any one (or combination of) risk factor. Several meta-analyses have
been published (4,66-68), but they either do not evaluate these studies according to the different
populations just mentioned, or soon become out-of-date because of publications of new RCTs.

**Recommendations for clinical use of progestogens for prevention of preterm birth:** (Table 3
and Figure 1)

- There is insufficient evidence to recommend the use of progestogens in singleton
gestations with no prior preterm birth, and unknown CL. *(Level I and III evidence, level A
  recommendation)*

- In women with singleton gestations, no prior SPTB, and short TVU CL ≤20 mm at ≤24
  weeks, vaginal progesterone, either 90mg gel or 200mg suppository, is associated with reduction
  in PTB and perinatal morbidity and mortality, and can be offered in these cases. *(Level I
  evidence, level A recommendation)*

- The issue of universal TVU CL screening of singleton gestations without prior PTB for
  the prevention of preterm birth remains object of debate. Cervical length screening in singleton
  gestations without prior preterm birth cannot yet be universally mandated. Nonetheless,
  implementation of such a screening strategy can be viewed as reasonable, and can be considered
  by individual practitioners. Given the impact on prenatal care and potential misuse of universal
screening, stretching the criteria and management beyond those tested in RCTs should be prevented. Practitioners who decide to implement universal TVU CL screening should follow strict guidelines. Practitioners who choose to screen low-risk singleton gestations may consider offering vaginal progesterone, either 90mg gel or 200mg suppositories, for short TVU CL ≤20 mm at ≤24 weeks. *(Level I and III evidence, level B recommendation)*

- In singleton gestations with prior SPTB 20-36 6/7 weeks, 17P 250mg IM weekly preferably starting at 16-20 weeks until 36 weeks is recommended. In these women, if the TVU CL shortens to <25mm before 24 weeks, cervical cerclage may be offered. *(Level I and III evidence, level A and B recommendations)*

- Progestogens have not been associated with prevention of PTB in multiple gestations, PTL, or PPROM. There is insufficient evidence to recommend the use of progestogens in women with any of these risk factors, with or without a short CL. Some experts offer 17P to women with a prior spontaneous PTB and a current multiple gestation, but there is insufficient data to evaluate the risks and benefits of this intervention in this population. *(Level I, II and III evidence, level B recommendation)*
References


http://www.fda.gov/AdvisoryCommittees/Calendar/ucm279859.htm. Last accessed on March 5, 2012. (Level III)


33. Lockwood CJ. The real progesterone story. Contemp Ostet Gynecol 2011;5:10-5. (Level III)


41. da Fonseca EB, Bittar RE, Carvalho MH, Sugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm


58. Iams JD, Berghella V. Care for women with prior preterm birth. Am J Obstet Gynecol. 2010;203:89-100. (Level III)

59. Durnwald CP, Momirova V, Rouse DJ, et al. For the Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units
Network. Second trimester cervical length and risk of preterm birth in women with twin gestations treated with 17-α hydroxyprogesterone caproate. J Matern Fetal Neonat Med 2010;e1-5. (Level II-1)


The quality of evidence for each included article was evaluated according to the categories outlined by the U.S. Preventative Services taskforce.

I Properly powered and conducted randomized controlled trial (RCT); well-conducted systematic review or meta-analysis of homogeneous RCTs

II-1 Well-designed controlled trial without randomization

II-2 Well-designed cohort or case-control analytic study

II-3 Multiple time series with or without the intervention; dramatic results from uncontrolled experiments

III Opinions of respected authorities, based on clinical experience; descriptive studies or case reports; reports of expert committees

Recommendations were graded in the following categories:

Level A The recommendation is based on good and consistent scientific evidence.
Level B: The recommendation is based on limited or inconsistent scientific evidence.

Level C: The recommendation is based on expert opinion or consensus.

This opinion was developed by the Publications Committee of the Society for Maternal-Fetal Medicine with the assistance of Vincenzo Berghella, and was approved by the Executive Committee of the Society on March 11, 2012. Dr. Berghella, and each member of the Publications Committee (Vincenzo Berghella, M.D. [Chair], Sean Blackwell, M.D. [Vice-Chair], Brenna Anderson, M.D., Sunet P. Chauhan, M.D., Joshua Copel, M.D., Cynthia Gyamfi, M.D., Donna Johnson M.D., Brian Mercer M.D., George Saade, M.D., Hyagriv Simhan, M.D., Lynn Simpson, M.D., Joanne Stone, M.D., Alan Tita, MD, Michael Varner, M.D, Ms. Deborah Gardner) have submitted a conflict of interest disclosure delineating personal, professional, and/or business interests that might be perceived as a real or potential conflict of interest in relation to this publication.

Disclaimer: The practice of medicine continues to evolve, and individual circumstances will vary. This opinion reflects information available at the time of its submission for publication and is neither designed nor intended to establish an exclusive standard of perinatal care. This
publication is not expected to reflect the opinions of all members of the Society for Maternal-Fetal Medicine.

**Legend to figure**

Algorithm for use of progestogens in prevention of preterm birth in clinical care
Table 1

Proposed mechanisms of action reported for progestogens to prevent preterm birth\textsuperscript{9-17}

<table>
<thead>
<tr>
<th>Mechanisms</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Stimulate transcription of ZEB1 and ZEB2, which inhibit connexin 43 (a gap-junction protein that helps synchronize contractile activity) and the oxytocin-receptor gene</td>
<td></td>
</tr>
<tr>
<td>Decrease prostaglandin synthesis, infection-mediated cytokine production (anti-inflammatory effects) by the fetal membranes/placenta</td>
<td></td>
</tr>
<tr>
<td>Changes in progesterone receptor (PR)-A and PR-B expression (decreased PR-A/PR-B ratio keeps uterus quiescent)</td>
<td></td>
</tr>
<tr>
<td>Membrane-bound PR in myometrium</td>
<td></td>
</tr>
<tr>
<td>Progesterone receptors, when stimulated by progesterone, help selected gene promotion, or prevent the binding of other factors</td>
<td></td>
</tr>
<tr>
<td>Interfere with cortisol-mediated regulation of placental gene expression</td>
<td></td>
</tr>
<tr>
<td>Non-genomic pathways</td>
<td></td>
</tr>
<tr>
<td>Reduce cervical stromal degradation in the cervix</td>
<td></td>
</tr>
<tr>
<td>Alter barrier to ascending inflammation/infection in the cervix</td>
<td></td>
</tr>
<tr>
<td>Reduce contraction frequency in the myometrium</td>
<td></td>
</tr>
<tr>
<td>Attenuate response to hemorrhage/inflammation in the decidua</td>
<td></td>
</tr>
<tr>
<td>Alter estrogen synthesis in the fetal membranes/placenta</td>
<td></td>
</tr>
<tr>
<td>Alter fetal endocrine-mediated effects</td>
<td></td>
</tr>
</tbody>
</table>

ZEB1 and ZEB2, zinc finger E-box binding homeobox proteins 1 and 2.
### Table 2

**Cervical length as a screening test in singleton gestations**

<table>
<thead>
<tr>
<th>Characteristic of screening test: Disease</th>
<th>Comments</th>
<th>TVU fulfills criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disease is clinically important</td>
<td>PTB: #1 cause of perinatal mortality and morbidity in developed countries; associated with one million deaths annually worldwide</td>
<td>Yes</td>
</tr>
<tr>
<td>Disease is clearly defined</td>
<td>Birth &lt;37 weeks</td>
<td>Yes</td>
</tr>
<tr>
<td>Disease prevalence is well known</td>
<td>12% in US, about 10% worldwide</td>
<td>Yes</td>
</tr>
<tr>
<td>Disease natural history is known / Recognizable early asymptomatic phase</td>
<td>First cervical changes associated with later PTB occur at the internal os, and can only be detected early by ultrasound</td>
<td>Yes</td>
</tr>
</tbody>
</table>

**Screening**

| Screening technique well-described | Described in several articles (30,31) | Yes |
| Screening is safe and acceptable   | TVU is safe even in women with PPROM (30); 99% of women would have TVU again; <2% have severe pain (33) | Yes |
| Screening has a reasonable cutoff identified | 20mm is the 5th percentile, 25mm is the 10% percentile in the general US population (30) | Yes |
| Results are reproducible (reliable) | <10% intra- and inter- observer variability | Yes; extremely important to control quality of TVU CL |
| Results are accurate (valid)        | Better than manual exam; predictive in all populations studied | Yes |

**Intervention, cost-effectiveness, and feasibility**

| ‘Early’ intervention is effective | Two positive randomized trials both reported that using vaginal | Yes |
progesterone for short CL is effective in preventing PTB (23,24,26)

| Screening and treating abnormals is cost-effective | Two cost-effectiveness manuscripts published (27,28) | Yes, in fact cost-saving |
| Facilities for screening are readily available | All pregnancies are offered an ultrasound for fetal anatomy screening at around 18-24 weeks | Yes, but must be properly organized |
| Facilities for treatment are readily available | Vaginal progesterone is easily administered as outpatient | Yes |

TVU, transvaginal cervical length; CL, cervical length; PTB, preterm birth.

Table 3

Current SMFM recommendations regarding use of progestogens for prevention of preterm birth

<table>
<thead>
<tr>
<th>Population</th>
<th>Recommendation regarding use of progestogens</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Asymptomatic</strong></td>
<td></td>
</tr>
</tbody>
</table>

Singletons without prior SPTB and unknown or normal TVU CL

No evidence of effectiveness

Singletons with prior SPTB

17P 250mg IM weekly from 16-20 weeks until 36 weeks

Singletons without prior SPTB but CL ≤20mm at ≤ 24 weeks

Vaginal progesterone 90mg gel or 200mg suppository daily from diagnosis of short CL until 36 weeks

Multiple gestations

No evidence of effectiveness

**Symptomatic**

PTL

No evidence of effectiveness
<table>
<thead>
<tr>
<th>PPROM</th>
<th>No evidence of effectiveness</th>
</tr>
</thead>
</table>

17P, 17-alpha hydroxyl-progesterone caproate; SPTB, spontaneous preterm birth; TVU, transvaginal ultrasound; CL, cervical length
PTB, preterm birth; TVU, transvaginal ultrasound; CL, cervical length; ^250 mg IM every week from 16-20 weeks to 36 weeks; *e.g. daily 200 mg suppository or 90mg gel from time of diagnosis of short CL to 36 weeks